ANTI-MIF ANTIBODIES IN THE TREATMENT OF CANCERS CONTAINING MUTANT TP53 AND/OR MUTANT RAS

The present invention pertains to anti-MIF antibodies, preferably in combination with cancer therapeutics, i.e. chemotherapeutic agents, in the treatment of cancers containing mutant TP53 and/or mutant RAS.

Saved in:
Bibliographic Details
Main Authors YAZJI, Salim, KERSCHBAUMER, Randolf, DOUILLARD, Patrice, THIELE, Michael
Format Patent
LanguageEnglish
French
German
Published 28.03.2018
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present invention pertains to anti-MIF antibodies, preferably in combination with cancer therapeutics, i.e. chemotherapeutic agents, in the treatment of cancers containing mutant TP53 and/or mutant RAS.
Bibliography:Application Number: EP20160724372